HomeSGX-LISTED COMPANIESShangri-La Asia Limited: 2025 Interim Results

Shangri-La Asia Limited: 2025 Interim Results

Published on

spot_img

For the first half of 2025, Shangri-La Asia Limited navigated market headwinds, leading to a decrease in overall profit. Despite these challenges, the Group maintained stable operational cash flow and upheld its commitment to shareholder returns.

• Brand Innovation: Discover the launch of a distinctive new luxury brand, aiming to elevate guest experiences and enhance investment returns across the portfolio

• Financial Acumen: Learn about strategic funding diversification and bond issuances at favourable rates, reflecting strong market confidence

• Operational Stability: Explore how the company maintained steady cash flow and remained focused on guest satisfaction and thoughtful expansion

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...